Vaderis raised $152M to run the first Phase 3 in HHT, a disease with no approved therapy
A 13-person startup raised $152 million to run a global Phase 3 in HHT, a rare vascular disorder with no approved therapy. The data that could make engasertib the first approved treatment, and the risks that remain.